These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

70 related items for PubMed ID: 6088045

  • 1. Effect of frequency of administration on therapeutic efficacy of cefotaxime.
    Parker RH.
    Clin Ther; 1984; 6(4):488-99. PubMed ID: 6088045
    [Abstract] [Full Text] [Related]

  • 2. Limiting cefotaxime pediatric dosing to adult standards: a pharmacokinetic simulation study.
    Dulaney Lopez AM, Rodriguez JC, Lopez-Samblas AM, Estes KS.
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):269-74. PubMed ID: 10395117
    [Abstract] [Full Text] [Related]

  • 3. Cefotaxime vs nafcillin and tobramycin for the treatment of serious infection. Comparative cost-effectiveness.
    Moore RD, Smith CR, Holloway JJ, Lietman PS.
    Arch Intern Med; 1986 Jun; 146(6):1153-7. PubMed ID: 3087307
    [Abstract] [Full Text] [Related]

  • 4. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ, Birmingham MC, Paladino JA, Carr JR, Hyatt JM, Forrest A, Zimmer GS, Adelman MH, Cumbo TJ.
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of ceftizoxime administered twice daily in hospitalized patients with respiratory tract infections.
    Lentnek A, Wikler M, McDevitt J, Sohn C.
    Clin Ther; 1984 Dec; 7(1):33-9. PubMed ID: 6097357
    [Abstract] [Full Text] [Related]

  • 7. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study.
    Rimola A, Salmerón JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, Guarner C, Planas R, Solá R, Vargas V.
    Hepatology; 1995 Mar; 21(3):674-9. PubMed ID: 7875666
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Review and reassessment of dosing schedules for cefotaxime in selected medical indications.
    Young LS.
    Diagn Microbiol Infect Dis; 1995 Mar; 22(1-2):147-54. PubMed ID: 7587030
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Therapeutic options for cefotaxime in the management of bacterial infections.
    Raddatz JK, Ostergaard BE, Rotschafer JC.
    Diagn Microbiol Infect Dis; 1995 Mar; 22(1-2):77-83. PubMed ID: 7587054
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital.
    Patel GW, Duquaine SM, McKinnon PS.
    Pharmacotherapy; 2007 Dec; 27(12):1637-43. PubMed ID: 18041884
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ceftriaxone therapy of meningitis and serious infections.
    Steele RW.
    Am J Med; 1984 Oct 19; 77(4C):50-3. PubMed ID: 6093519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.